KRAS and neoplasm: Taking in situ repair of single-gene mutations as an example, Sayed’s team used Prime Editor (PE3 system) to target correction of KRAS G12D mutation in a pancreatic cancer model, resulting in tumor growth inhibition of 55% without significant off-target effect (Sayed et al., 2022).